Both stereoselective (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinoline enantiomers protect striatal terminals against rotenone-induced suppression of dopamine release

Neurotoxicity Research

Volumn 20, Issue 2, 2011, Pages 134-149

  Antkiewicz Michaluk, Lucyna ^a   Wąsik, Agnieszka ^a   Romańska, Irena ^a   Bojarski, Andrzej ^a   Michaluk, Jerzy ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

(R) and (S) 1MeTIQ; Dopamine metabolism; Dopamine release; Locomotor activity; Neuroprotection; Rat; Rotenone; Stereoselective enantiomers; Striatum

Indexed keywords

1 METHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; ROTENONE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG STRUCTURE; ENANTIOMER; ENZYME DEGRADATION; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LOCOMOTION; MALE; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY;

MAMMALIA; RATTUS; RODENTIA;

EID: 80052641922     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-010-9228-5     Document Type: Article

References (72)

1. Abe K, Taguchi K, Wasai T, Ren J, Utsunomiya I, Shinohara T, Miyatake T, Sano T (2001) Stereoselective effect of (R)- and (S)- 1-methyl-1,2,3,4- tetrahydroisoquinolines on mouse model of Parkinson's disease. Brain Res Bull 56:55-60 (Pubitemid 32962939)
2. Abe K, Saitoh T, Horiguchi Y, Utsunomiya I, Taguchi K (2005) Synthesis and neurotoxicity of tetrahydroisoquinoline derivatives for studying Parkinson's disease. Biol Pharm Bull 28:1355-1362 (Pubitemid 41379680)
3. Alam M, Schmidt WJ (2002) Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136:317-324 (Pubitemid 35246417)
4. Antkiewicz-Michaluk L (2004) Neuroprotective effects of 1-methyl- 1,2,3,4-tetrahydroisoquinoline: in vitro and in vivo studies in rats. Pol J Pharmacol 56(Suppl):179
5. Antkiewicz-Michaluk L, Vetulani J (2001) Tetrahydroisoquinolines as endogenous neurotoxins and neuroprotectants. Acta Neurobiol Exp 61:246
6. Antkiewicz-Michaluk L, Michaluk J, Romańska I, Papla I, Vetulani J (2000a) Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol. J Neural Transm 107:1009-1019
7. Antkiewicz-Michaluk L, Romańska I, Papla I, Michaluk J, Bakalarz M, Vetulani J, Krygowska-Wajs A, Szczudlik A (2000b) Neurochemical changes induced by acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline and salsolinol in dopaminergic structures of rat brain. Neuroscience 96:59-64 (Pubitemid 30103603)
8. Antkiewicz-Michaluk L, Michaluk J, Mokrosz M, Romańska I, Lorenc-Koci E, Ohta S, Vetulani J (2001) Different action on dopamine catabolic pathways of two endogenous 1,2,3,4- tetrahydroisoquinolines with similar antidopaminergic properties. J Neurochem 78:100-108 (Pubitemid 32622592)
9. Antkiewicz-Michaluk L, Karolewicz B, Romańska I, Michaluk J, Bojarski AJ, Vetulani J (2003) 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol 466:263-269 (Pubitemid 36412089)
10. Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romańska I, Bojarski A, Vetulani J (2004) Protective effect of 1-methyl-1,2,3,4- tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol 7:155-163 (Pubitemid 38823282)
11. Antkiewicz-Michaluk L, Filip M, Kostowski W, Patsenka A, Popik P, Przegaliński E, Wróbel M (2005) 1-Methyl-1,2,3,4- tetrahydroisoquinoline attenuates ethanol, cocaine and morphine addiction in behavioral models: neurochemical correlates. Acta Neurobiol Exp 65:301-321
12. Antkiewicz-Michaluk L, Łazarewicz JW, Patsenka A, Kajta M, Ziemińska E, Salińska E, Wa̧sik A, Gołembiowska K, Vetulani J (2006) The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J Neurochem 97:846-856
13. Antkiewicz-Michaluk L, Filip M, Michaluk J, Romańska I, Przegalin ́ski E, Vetulani J (2007) An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoqunoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats. J Neural Transm 114:307-317 (Pubitemid 46328651)
14. Antkiewicz-Michaluk L, Romańska I, Boksa J, Bojarski A, Michaluk J (2009) Different neurochemical effects of (R)- and (S)- enantiomers of tetrahydroisoquinoline on dopamine metabolism in rat brain. Eur Neuropsychopharmacol 19(Suppl 3):S261
15. Avshalumov MV, Rice ME (2003) Activation of ATP-sensitive K+(K(ATP)) channels by H2O2 underlies glutamate-dependent inhibition of striatal dopamine release. Proc Natl Acad Sci USA 100:11729-11734 (Pubitemid 37206003)
16. Avshalumov MV, Chen BT, Koos T, Tepper JM, Rice ME (2005) Endogenous hydrogen peroxide regulates the excitability of midbrain dopamine neurons via ATP-sensitive potassium channels. J Neurosci 25:4222-4231 (Pubitemid 40628766)
17. Bankiewicz KS, Oldfield EH, Chiueh CC, Doppman JL, Jacobowitz DM, Kopin IJ (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP). Life Sci 39:7-16 (Pubitemid 16090932)
18. Bao L, Avshalumov MV, Rice ME (2005) Partial mitochondrial inhibition causes striatal dopamine release suppression and medium spiny neuron depolarization via H2O2 elevation, not ATP depletion. J Neurosci 25:10029-10040 (Pubitemid 41528042)
19. Beal MF, Brouillet E, Jenkins B, Henshaw R, Rosen B, Hyman BT (1993) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 61:1147-1150 (Pubitemid 23241258)
20. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306
21. Bowton E, Sauders C, Erreger K, Sakrikar D, Mathies HJ, Sen N, Jessen T et al (2010) Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J Neurosci 30:6048-6057
22. Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S, Nacci V et al (2003) Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem 46:3822-3839 (Pubitemid 37034135)
23. Chen PC, Lao CL, Chen JC (2009) The D(3) dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5. J Neurochem 110:1180-1190
24. Egan MF, Karoum F, Wyatt RJ (1991) Effects of acute and chronic clozapine and haloperidol administration on 3-methoxytyramine accumulation in the rat prefrontal cortex, nucleus accumbens and striatum. Eur J Pharmacol 199:191-199
25. Ferger B, Eberhardt O, Teismann P, de Groote C, Schulz JB (1999) Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation. J Neurochem 73:1329-1332 (Pubitemid 29395495)
26. Filip M, Antkiewicz-Michaluk L, Zaniewska M, Frankowska M, Gołda A, Vetulani J, Przegaliński E (2007) Effects of 1-methyl- 1,2,3,4-tetrahydroisoquinoline on the behavioral effects of cocaine in rats. J Physiol Pharmacol 58:625-639
27. Gao HM, Hong JS, Zhang W, Liu B (2002) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22:782-790 (Pubitemid 34141759)
28. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041 (Pubitemid 26383833)
29. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50:1346-1350 (Pubitemid 28240350)
30. Green JG, Greenmyre JT (1995) Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J Neurochem 64:430-436
31. Green JG, Porter RH, Eller RV, Greenmyre JT (1993) Inhibition of succinate dehydrogenase by malonic acid produces an ''excitotoxic'' lesion in rat striatum. J Neurochem 61:1151-1154 (Pubitemid 23241259)
32. Greenamyre JT, Betarbet R, Sherer T, Panov A (2001) Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci 24:247-252
33. Gutman M, Singer TP, Beinert H, Casida JE (1970) Reaction sites of rotenone, piericidin A, and amytal in relation to the nonheme iron components of NADH dehydrogenase. Proc Natl Acad Sci USA 65:763-770
34. Heikkila RE, Nicklas WJ, Vyas I, Duvoisin RC (1985) Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine toxicity. Neurosci Lett 62:389-394 (Pubitemid 16147750)
35. Horgan DJ, Singer TP, Casida JE (1968) Studies on the respiratory chain-linked reduced nicotinamide adenine dinucleotide dehydrogenase. 13. Binding sites of rotenone, piericidin A, and amytal in the respiratory chain. J Biol Chem 243:834-843
36. Jenner P (2001) Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci 24:245-247
37. Karoum F, Chrapusta SJ, Egan MF (1994) 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in frontal cortex, nucleus accumbens and striatum by a simple two pool model. J Neurochem 63:972-978
38. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93-96 (Pubitemid 9093798)
39. Kohno M, Ohta S, Hirobe M (1986) Tetrahydroisoquinoline and 1- methyltetrahydro-isoquinoline as novel endogenous amines in rat brain. Biochem Biophys Res Com 140:448-454 (Pubitemid 17190044)
40. Kotake Y, Tasaki Y, Makino Y, Ohta S, Hirobe M (1995) 1-Benzyl- 1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem 65:2633-2638
41. Kotake Y, Yoshida M, Ogawa M, Tasaki Y, Hirobe M, Ohta S (1996) Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate. Neurosci Lett 217:69-71 (Pubitemid 26342796)
42. Lamensdorf I, Eisenhofer G, Harvey-White J, Hayakawa Y, Kirk K, Kopin IJ (2000) Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4- dihydroxyphenylacetaldehyde. J Neurosci Res 60:552-558 (Pubitemid 30252918)
43. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980 (Pubitemid 13189531)
44. Le Foll B, Schwartz JC, Sokoloff P (2000) Dopamine D3 receptor agents as potential new medications for drug addiction. Eur Psych 15:140-146 (Pubitemid 30194159)
45. Liss B, Bruns R, Roeper J (1999) Alternative sulfonylurea receptor expression defines metabolic sensitivity of K-ATP channels in dopaminergic midbrain neurons. EMBO J 18:833-846 (Pubitemid 29082263)
46. Lorenc-Koci E, Śmiałowska M, Antkiewicz-Michaluk L, Gołembiowska K, Bajkowska M, Wolfarth S (2000) Effect of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra in rat. Neuroscience 95:1049-1059 (Pubitemid 30006893)
47. Lorenc-Koci E, Antkiewicz-Michaluk L, Wardas J, Zapała M, Wierońska J (2004) Effect of 1,2,3,4-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12, 935 to dopamine transporter in the rat nigrostriatal dopaminergic system. Brain Res 1009:67-81 (Pubitemid 38553849)
48. Lorenc-Koci E, Gołembiowska K, Wardas J (2005) 1,2,3,4-Tetrahydroisoquinoline protects terminals of dopaminergic neurons in the striatum against the malonate-induced neurotoxicity. Brain Res 1051:145-154 (Pubitemid 40982636)
49. Lotharius J, O'Malley KL (2000) The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 275:38581-38588 (Pubitemid 32009186)
50. Marey-Semper I, Gelman M, Levi-Strauss M (1993) The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra. Eur J Neurosci 5:1029-1034 (Pubitemid 23239788)
51. Miller J, Selhub J, Joseph J (1996) Oxidative damage caused by free radicals produced during catecholamine autooxidation: protective effects of O-methylation and melatonin. Free Radic Biol Med 21:241-249 (Pubitemid 26255201)
52. Moy LY, Zeevalk GD, Sonsalla PK (2000) Role for dopamine in malonate-induced damage in vivo in striatum an in vitro in mesencephalic cultures. J Neurochem 74:1656-1665 (Pubitemid 30163988)
53. Nagatsu T (1997) Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res 29:99-111 (Pubitemid 27422504)
54. Nakamura K, Bindokas VP, Marks JD, Wright DA, Frim DM, Miller RJ, Kang UJ (2000) The selective toxicity of 1-methyl-4- phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol Pharmacol 58:271-278 (Pubitemid 30497470)
55. Niwa T, Takeda N, Kaneda N, Hashizume Y, Nagatsu T (1987) Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroisoquinoline in parkinsonian and normal human brains. Biochem Biophys Res Commun 144:1084-1089 (Pubitemid 17078794)
56. Ohta S, Kohno M, Makino Y, Tachikawa O, Hirobe M (1987) Tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline are present in the human brain: relation to Parkinson's disease. Biomed Res 8:453-456
57. Patsenka A, Antkiewicz-Michaluk L (2004) Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds, 1,2,3,4-tetrahydroisoquinoline alkaloids. Pol J Pharmacol 56:727-734 (Pubitemid 40287474)
58. Santiago M, Granero L, Machado A, Cano J (1995) Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine. Eur J Pharmacol 280:251-256
59. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823-827
60. Shi WX (2009) Electrophysiological characteristics of dopamine neurons: a 35-year update. J Neural Transm 73:103-119
61. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JPJ, Davis RE, Parker WDJ (1996) Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40:663-671 (Pubitemid 26357892)
62. Tasaki Y, Makino Y, Ohta S, Hirobe M (1991) 1-Methyl-1,2,3,4- tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6- tetrahydropiridine-treated mouse, prevents parkinsonism-like behavior abnormalities. J Neurochem 57:1940-1943 (Pubitemid 21922843)
63. Testa CM, Sherer TB, Greenamyre JT (2005) Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 134:109-118 (Pubitemid 40403643)
64. Thiffault C, Langston JW, Di Monte DA (2000) Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res 885:283-288
65. Wang X, Chen S, Ma G, Ye M, Lu G (2005) Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2? disturbances in microglia activation-mediated dopaminergic cell degeneration. Mech Ageing Dev 126:1241-1254 (Pubitemid 41572241)
66. Wa̧sik A, Romańska I, Antkiewicz-Michaluk L (2007) The effect of an endogenous compound 1-methyl-1,2,3,4-tetrahydroisoquinoline on morphine-induced analgesia, dependenceand neurochemical changes in dopamine metabolism in rat brain structures. J Physiol Pharmacol 58:235-252 (Pubitemid 47026559)
67. Wa̧sik A, Michaluk J, Romańska I, Bojarski A, Antkiewicz-Michaluk L (2009a) The comparison of effects of the endogenous enantiomer, (R)- with the racemate (R, S)-1-methyl-1,2,3,4- tetrahydroisoquinoline on dopamine metabolism in the brain structures and its in vivo release in rat striatum. Pharmacol Rep 61:366-367
68. Wa̧sik A, Romańska I, Antkiewicz-Michaluk L (2009b) 1-Benzyl- 1,2,3,4-tetrahydroisoquinoline, an endogenous parkinsonisminducing toxin, strongly potentiates MAO-dependent dopamine oxidation and impairs dopamine release: ex vivo and in vivo neurochemical studies. Neurotox Res 15:15-23
69. Wróbel M (2005) 1-Methyl-1,2,3,4-tetrahydroisoquinoline attenuates ethanol, cocaine and morphine addiction in behavioral models: neurochemical correlates. Acta Neurobiol Exp 65:(P3.01):321
70. Yamakawa T, Ohta S (1999) Biosynthesis of a parkinsonismpreventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction. Neurosci Lett 259:157-160 (Pubitemid 29059608)
71. Yamakawa T, Kotake Y, Fujitani M, Shintani H, Makino Y, Ohta S (1999) Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Neurosci Lett 276:68-70 (Pubitemid 29525527)
72. Zeevalk GD, Derr-Yellin E, Nicklas WJ (1995) Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3- nitropropionic acid and protection by NMDA receptor blockade. J Pharmacol Exp Ther 275:1124-1130 (Pubitemid 26129913)